NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon

WELLESLEY HILLS, Massachusetts, June 1, 2011 -

NMT Medical, Inc. will sell its BioTREK technology platform, which has
been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn,
Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical
creditors, at its sealed bid sale of June 10, 2011.

BioTREK is a technology platform that utilizes a novel bioabsorbable
polymer to create a family of percutaneous devices for repair or remodeling
of intracardiac defects including patent foramen ovale (PFO), atrial septal
defect (ASD) and left atrial appendage (LAA). Unlike other bioabsorbable
cardiac implants, BioTREK implants are rendered radiopaque for fluoroscopic
visualization using a proprietary technology developed by NMT Medical.

The intellectual property, patents, etc. will be sold at a sealed bid
sale on Friday, June 10, 2011 at noon. Persons interested in bidding must
sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's
Office - jffinnjr@finnwarnkegayton.com or +1-781-237-8840. They will then
receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn,
Warnke & Gayton (www.finnwarnkegayton.com), Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the
area of management consulting for distressed enterprises, bankruptcy
accounting and related matters, such as assignee for the benefit of creditors
and liquidating agent for a corporation. He has been involved in a number of
loan workouts and bankruptcy cases for thirty-seven (37) years. His most
recent Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX
Pharmaceuticals, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegayton.com.

.